This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
account_circleSign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Management of myoclonic seizures

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Pharmacological treatment of myoclonic seizures

First-line treatment in children, young people and adults with myoclonic seizures

  • sodium valproate should be offered as first-line treatment to children, young people and adults with newly diagnosed myoclonic seizures, unless it is unsuitable. Follow the MHRA safety advice on sodium valproate
  • levetiracetam or topiramate should be considered if sodium valproate is unsuitable or not tolerated. Be aware that topiramate has a less favourable side-effect profile than levetiracetam and sodium valproate. Follow the MHRA safety advice on sodium valproate

Adjunctive treatment in children, young people and adults with myoclonic seizures

  • levetiracetam, sodium valproate or topiramate should be offered as adjunctive treatment to children, young people and adults with myoclonic seizures if first-line treatments are ineffective or not tolerated. Follow the MHRA safety advice on sodium valproate

Reference:

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.